We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

56 hedge funds and large institutions have $5.99M invested in Oramed Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

111% more call options, than puts

Call options by funds: $158K | Put options by funds: $75K

12% more funds holding

Funds holding: 50 → 56 (+6)

0.01% more ownership

Funds ownership: 5.69% → 5.7% (+0.01%)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

27% less capital invested

Capital invested by funds: $8.15M → $5.99M (-$2.16M)

Holders
56
Holders Change
+6
Holders Change %
+12%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
12
Reduced
13
Closed
6
Calls
$158K
Puts
$75K
Net Calls
+$83K
Net Calls Change
-$367K

Top Buyers

Rank Fund Capital Flow
1
RG
Rathbones Group
United Kingdom
+$913K
2
Goldman Sachs
Goldman Sachs
New York
+$197K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$85.9K
4
LPL Financial
LPL Financial
California
+$66.1K
5
Squarepoint
Squarepoint
New York
+$58.8K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$281K
2
GCP
GSA Capital Partners
United Kingdom
-$238K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$234K
4
BCM
BML Capital Management
Indiana
-$216K
5
SRC
Samson Rock Capital
United Kingdom
-$132K
Name Holding Trade Value Shares
Change 		Change in
Stake
AS
26
Altshuler Shaham
Israel
$33.4K – – –
GJIA
27
Glass Jacobson Investment Advisors
Maryland
$32K – – –
Wealth Enhancement Advisory Services
28
Wealth Enhancement Advisory Services
Minnesota
$31.1K +$37.5K +11,900 New
CAM
29
Close Asset Management
United Kingdom
$30K – – –
Prudential Financial
30
Prudential Financial
New Jersey
$29.2K – – –
Jane Street
31
Jane Street
New York
$28.5K -$90.1K -28,613 -72%
Group One Trading
32
Group One Trading
Illinois
$27.4K +$33K +10,495 New
Invesco
33
Invesco
Georgia
$26.3K +$31.8K +10,094 New
Qube Research & Technologies (QRT)
34
Qube Research & Technologies (QRT)
United Kingdom
$25.8K +$31.1K +9,890 New
UBS Group
35
UBS Group
Switzerland
$16.2K +$202 +64 +1%
BCM
36
Bourgeon Capital Management
Connecticut
$14.7K – – –
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$14K +$16.6K +5,273 New
HNB
38
Huntington National Bank
Ohio
$13.1K – – –
Wells Fargo
39
Wells Fargo
California
$11.7K -$4.72K -1,500 -25%
Simplex Trading
40
Simplex Trading
Illinois
$6K -$11.3K -3,600 -59%
TRCT
41
Tower Research Capital (TRC)
New York
$5.85K -$22.4K -7,102 -76%
ME
42
McIlrath & Eck
Washington
$5.22K -$1.57K -500 -20%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$4.78K – – –
IA
44
IFP Advisors
Florida
$4.53K – – –
Northwestern Mutual Wealth Management
45
Northwestern Mutual Wealth Management
Wisconsin
$4.11K – – –
CHC
46
City Holding Co
West Virginia
$2.78K – – –
CFGS
47
Concourse Financial Group Securities
Alabama
$2.61K – – –
TWC
48
TD Waterhouse Canada
Ontario, Canada
$2.55K – – –
QT
49
Quantbot Technologies
New York
$2.43K +$2.93K +931 New
Fidelity Investments
50
Fidelity Investments
Massachusetts
$2.35K +$2.83K +900 New
1
2
3

ORMP Hedge Fund Activity: Q3 2023 in Review

56 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2023, worth a combined $5.99M — down 27% from $8.15M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ORMP positions and 6 closed out — a net gain of 8 holders — while 12 added to existing stakes and 13 trimmed.

The largest buyer was Rathbones Group, opening a new position worth an estimated $913K. The largest seller was Millennium Management, exiting entirely with an estimated $281K sold.

  • 56 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2023, up from 50 in Q2 2023.
  • Funds reported $5.99M of Oramed Pharmaceuticals stock for Q3 2023, down 27% quarter-over-quarter.
  • 14 funds opened new Oramed Pharmaceuticals positions in Q3 2023 and 6 closed out, a net change of +8 holders.
  • The largest Oramed Pharmaceuticals buyer in Q3 2023 was Rathbones Group, an estimated $913K added.
  • The largest Oramed Pharmaceuticals seller in Q3 2023 was Millennium Management, an estimated $281K sold.

Based on aggregated 13F filings for Q3 2023.